131 investors have funded 38 Life Sciences companies head-officed in Nanjing, across 166 rounds (Dec 2010 – Jan 2025). They are ranked by how many Nanjing companies in this market they have actually backed.
"In Nanjing" describes the companies, not the investor: most of the money in any city comes from somewhere else, and the Where the money comes from section below shows exactly where it came from here.
Ranked by companies backed in this market and city, then by round count. "Led" counts rounds recorded with this investor as lead.
| # | Investor | Based in | Stages here | Companies | Rounds | Led | Latest | Portfolio total |
|---|---|---|---|---|---|---|---|---|
| 1 | Lilly Asia Ventures | Shanghai | Series CSeries DSeries B | 3 | 7 | 2 | Apr 2024 | 104 |
| 2 | IDG Capital | New York City, United States | Series A | 3 | 3 | 1 | Apr 2022 | 636 |
| 3 | Addor Capital | Nanjing, China | UnattributedSeries BSeries A | 3 | 3 | 1 | Dec 2022 | 158 |
| 4 | Kaitai Capital Management | Hangzhou, China | Series ASeedAngel | 3 | 3 | 1 | Aug 2022 | 49 |
| 5 | Jinmao Investment | Nanjing, China | UnattributedSeries CSeries A | 3 | 3 | 2 | Jan 2024 | 30 |
| 6 | Nanjing Innovation Capital Group | Nanjing, China | Series ASeed | 3 | 3 | — | Jan 2023 | 18 |
| 7 | Decheng Capital | Shanghai, China | Series CSeries ASeries B | 2 | 4 | 3 | Jun 2022 | 60 |
| 8 | Qiming Venture Partners | Shanghai, China | Series ASeed | 2 | 2 | 1 | Jan 2025 | 337 |
| 9 | Hillhouse | New York City, United States | Series B | 2 | 2 | 2 | Sep 2020 | 341 |
| 10 | Sequoia Capital China | Beijing | SeedSeries B | 2 | 2 | 2 | Feb 2022 | 345 |
| 11 | Shenzhen Capital Group | Shenzhen, China | Series CSeries B | 2 | 2 | — | Mar 2021 | 372 |
| 12 | CDH | Kowloon, China | Series ASeries C | 2 | 2 | 2 | Sep 2021 | 224 |
| 13 | TF Capital | Shanghai, China | Series BSeries A | 2 | 2 | 1 | Nov 2021 | 36 |
| 14 | Octagon Capital Advisors | New York City, United States | Series BSeries A | 2 | 2 | 1 | Nov 2021 | 30 |
| 15 | Shanghai Guoxin Investment Development | Xuhui, China | Series CSeries B | 2 | 2 | 2 | Sep 2023 | 14 |
| 16 | Dingxin Capital | Xicheng, China | SeedSeries D | 2 | 2 | — | May 2024 | 6 |
| 17 | Nanjing Jiangbei New Area | China | Series CSeries A | 2 | 2 | — | Jan 2023 | 5 |
| 18 | Yunqi Partners | Beijing, China | Series ASeries B | 1 | 2 | — | Jun 2021 | 115 |
| 19 | Legend Star | Beijing, China | Series ASeed | 1 | 2 | 2 | Oct 2020 | 104 |
| 20 | Guangzhou Yuexiu Industrial Investment Fund Management | Guangzhou, China | Series BSeries D | 1 | 2 | — | Mar 2022 | 44 |
| 21 | Dalton Venture | Shanghai, China | Series ASeries B | 1 | 2 | 1 | Jun 2021 | 19 |
| 22 | Zi Niu Fund | Beijing, China | Series A | 1 | 2 | — | Oct 2020 | 11 |
| 23 | Nanjing Gaoke | Nanjing, China | Series A | 1 | 2 | — | Oct 2020 | 3 |
| 24 | Matrix Partners China | Chaoyang, China | Series B | 1 | 1 | 1 | Jun 2021 | 446 |
| 25 | Legend Capital | Haidian, China | Seed | 1 | 1 | 1 | Sep 2020 | 335 |
| 26 | Morgan Stanley | New York City, United States | Series B | 1 | 1 | 1 | Sep 2020 | 373 |
| 27 | RA Capital Management | Boston, United States | Series D | 1 | 1 | 1 | Mar 2020 | 317 |
| 28 | Northern Light Venture Capital | Beijing, China | Series B | 1 | 1 | — | Nov 2021 | 215 |
| 29 | Sinovation Ventures | Beijing, China | Series A | 1 | 1 | — | Feb 2015 | 235 |
| 30 | Gaorong Capital | Beijing, China | Seed | 1 | 1 | 1 | Aug 2022 | 203 |
| 31 | Morningside | Series A | 1 | 1 | 1 | Jun 2018 | 171 | |
| 32 | MassChallenge | Boston, United States | Seed | 1 | 1 | 1 | Jun 2016 | 254 |
| 33 | BlueRun Ventures | Menlo Park, United States | Series B | 1 | 1 | — | Mar 2021 | 156 |
| 34 | Oriental Fortune Capital | Shenzhen, China | Seed | 1 | 1 | — | Mar 2023 | 169 |
| 35 | Yunfeng Capital | Shanghai, China | Series B | 1 | 1 | 1 | Sep 2020 | 118 |
| 36 | Johnson & Johnson Innovation | New Brunswick, United States | Series D | 1 | 1 | 1 | Mar 2020 | 102 |
| 37 | Morningside | Newton, United States | Series B | 1 | 1 | — | Jun 2021 | 101 |
| 38 | Lenovo | Hong Kong, China | Series A | 1 | 1 | — | Aug 2018 | 85 |
| 39 | CoStone Capital | Shenzhen, China | Series C | 1 | 1 | 1 | Sep 2021 | 87 |
| 40 | Yuanbio Venture Capital | Suzhou, China | Series A | 1 | 1 | 1 | Mar 2019 | 79 |
| 41 | GF Xinde Investment Management | Guangzhou, China | Series B | 1 | 1 | 1 | Dec 2022 | 74 |
| 42 | 6 Dimensions Capital | Pudong, China | Series A | 1 | 1 | — | Jul 2014 | 54 |
| 43 | Volcanics Venture | Shanghai, China | Series A | 1 | 1 | — | Jun 2018 | 58 |
| 44 | CCB International | Series C | 1 | 1 | 1 | Sep 2021 | 59 | |
| 45 | Shenzhen Gaoxintou Group | Shenzhen, China | Series A | 1 | 1 | — | Jan 2022 | 60 |
| 46 | ShenZhen GTJA Investment Group | Shenzhen, China | Series D | 1 | 1 | 1 | Apr 2024 | 53 |
| 47 | CPE | Beijing, China | Series B | 1 | 1 | 1 | Jun 2021 | 53 |
| 48 | Delian Capital | Beijing, China | Seed | 1 | 1 | — | May 2024 | 50 |
| 49 | Share Capital | Shenzhen, China | Series C | 1 | 1 | 1 | Nov 2021 | 47 |
| 50 | Lotus Lake Capital Management | Haidian, China | Series B | 1 | 1 | — | May 2023 | 47 |
| 51 | China Everbright | Hong Kong, China | Series C | 1 | 1 | 1 | Sep 2021 | 40 |
| 52 | Oceanpine Capital | Beijing, China | Seed | 1 | 1 | — | Feb 2022 | 42 |
| 53 | THG Ventures | Beijing, China | Seed | 1 | 1 | — | Jan 2025 | 38 |
| 54 | GL Ventures | Fort Collins, United States | Series B | 1 | 1 | 1 | Mar 2021 | 39 |
| 55 | Cenova | Xuhui, China | Series A | 1 | 1 | — | Jul 2014 | 34 |
| 56 | 3E Bioventures Capital | Beijing, China | Series B | 1 | 1 | — | Nov 2021 | 31 |
| 57 | Efung Capital | Shenzhen, China | Series C | 1 | 1 | 1 | Jan 2023 | 34 |
| 58 | Medfine Capital | Beijing, China | Series A | 1 | 1 | — | Nov 2021 | 29 |
| 59 | Zhengxuan Investment | Shenzhen, China | Angel | 1 | 1 | — | Jun 2022 | 32 |
| 60 | VI Ventures | Hong Kong, China | Seed | 1 | 1 | — | Aug 2022 | 23 |
| 61 | Huatai Zijin Investment | Nanjing, China | Unattributed | 1 | 1 | — | Apr 2022 | 27 |
| 62 | Hudson Bay Capital | New York City, United States | Series D | 1 | 1 | 1 | Mar 2020 | 23 |
| 63 | C&D | Xiamen, China | Series D | 1 | 1 | — | Mar 2022 | 26 |
| 64 | Tembusu Partners | Singapore, Singapore | Series A | 1 | 1 | — | Dec 2010 | 25 |
| 65 | Huajin Capital | Zhuhai, China | Seed | 1 | 1 | 1 | Feb 2023 | 22 |
| 66 | GL Ventures | San Francisco, United States | Series C | 1 | 1 | 1 | Sep 2021 | 18 |
| 67 | Insight Capital | Beijing, China | Seed | 1 | 1 | — | Jan 2025 | 17 |
| 68 | Yangtze River Industry Fund | Hubei, China | Series C | 1 | 1 | — | Oct 2020 | 19 |
| 69 | LYZZ Capital | Huangpu, China | Series A | 1 | 1 | 1 | Apr 2022 | 15 |
| 70 | Tao Capital | Dongcheng, China | Series A | 1 | 1 | — | Dec 2021 | 17 |
| 71 | Jifeng Ventures | Jing'an, China | Series A | 1 | 1 | 1 | Apr 2022 | 17 |
| 72 | Longmen Capital | Shenzhen, China | Series A | 1 | 1 | — | Mar 2022 | 16 |
| 73 | Fangyi Equity Investment Fund | Chaoyang, China | Series B | 1 | 1 | — | Dec 2022 | 15 |
| 74 | Shenzhen Dingxin Capital Management | Shenzhen, China | Seed | 1 | 1 | — | Jan 2023 | 15 |
| 75 | HMC Ventures | Hangzhou, China | Series B | 1 | 1 | 1 | Apr 2023 | 12 |
| 76 | 3E BioVentures | Beijing, China | Series B | 1 | 1 | 1 | Dec 2021 | 13 |
| 77 | Firstred | Xicheng, China | Series A | 1 | 1 | — | Nov 2021 | 13 |
| 78 | Zhongbo Juli | Chaoyang, China | Seed | 1 | 1 | — | Feb 2023 | 10 |
| 79 | TigerYeah Capital | Hangzhou, China | Series A | 1 | 1 | — | Dec 2021 | 9 |
| 80 | Wuxi Xiecheng Enterprise Management | Wuxi, China | Series A | 1 | 1 | — | Oct 2022 | 10 |
| 81 | Longpan Investment | Beijing, China | Seed | 1 | 1 | — | May 2024 | 10 |
| 82 | Plaisance Capital Management | Natick, United States | Series C | 1 | 1 | 1 | Sep 2021 | 7 |
| 83 | Sherpa Invest | Anderlecht, Belgium | Series B | 1 | 1 | — | May 2023 | 9 |
| 84 | Daotong Investment | China | Series B | 1 | 1 | — | Jun 2021 | 8 |
| 85 | Juming Venture Capital | Suzhou, China | Series C | 1 | 1 | 1 | Nov 2021 | 8 |
| 86 | Ennovation Ventures | Shanghai, China | Series C | 1 | 1 | — | Oct 2020 | 8 |
| 87 | Exome Asset Management | New York City, United States | Series D | 1 | 1 | — | Mar 2022 | 7 |
| 88 | Xicheng Jinrui | Xicheng, China | Series D | 1 | 1 | 1 | Apr 2024 | 6 |
| 89 | CNCB Investment | Hong Kong, China | Series C | 1 | 1 | 1 | Sep 2021 | 6 |
| 90 | Huayi Capital | Shanghai, China | PE | 1 | 1 | 1 | Aug 2020 | 6 |
| 91 | Wenzhou Investment | Xuhui, China | Series A | 1 | 1 | — | Jan 2024 | 6 |
| 92 | C&D Emerging Industry Equity Investment | Series D | 1 | 1 | — | Apr 2024 | 4 | |
| 93 | Oceanpine Capital | Beijing, China | Series B | 1 | 1 | 1 | Dec 2020 | 5 |
| 94 | Zheshang Innovation Investment Group | Hangzhou, China | Series B | 1 | 1 | 1 | Dec 2020 | 4 |
| 95 | InnoMed Capital | Nanjing, China | Series A | 1 | 1 | — | Jan 2022 | 3 |
| 96 | Ningbo Research Institute of Fudan University | Ningbo, China | Angel | 1 | 1 | 1 | Feb 2023 | 3 |
| 97 | InnoVision Capital | San Francisco, United States | Series A | 1 | 1 | — | Jun 2018 | 2 |
| 98 | Shanghai Science and Technology Innovation Fund | Series B | 1 | 1 | — | Jun 2021 | 2 | |
| 99 | Lichen Capital | Seed | 1 | 1 | — | Aug 2022 | 2 | |
| 100 | Shanghai Alliance Financial Services | China | Series A | 1 | 1 | 1 | Jul 2020 | 2 |
Showing the top 100 of 131. Search the full investor set →
Head office of the investors on this page.
Rounds by stage — where in a company's life this money arrives.
Total disclosed size of each round, not one investor's share.
How active this market has been.
Life Sciences companies head-officed in Nanjing that took money from these investors.
| Company | Backers | Rounds | Disclosed | Latest round |
|---|---|---|---|---|
| Impact Therapeutics impacttherapeutics.com |
16 | 21 | $366.2M | Series D Apr 2024 |
| IASO BIO iasobio.com |
14 | 14 | $816M | Series C Jan 2023 |
| Triastek triastek.com |
12 | 14 | $475.3M | Series B Sep 2023 |
| Biosion biosion.com |
9 | 9 | $181.6M | Series B Apr 2023 |
| Help Stem Cell Innovations helpsci.com.cn |
8 | 11 | $122.4M | Series C Nov 2021 |
| GemPharmatech gempharmatech.com |
7 | 7 | $339.2M | Series B Sep 2020 |
| BioHeng bioheng.com |
6 | 8 | $425.3M | Angel Jun 2022 |
| Abrev Biotechnology abrevbio.com |
6 | 6 | $240M | Series A Nov 2021 |
| Nanjing Wei Li Zhi Bo Biotechnology leadsbiolabs.com |
6 | 6 | $178.7M | Series C Oct 2020 |
| Nanjing CART Medical Technologies cart-med.com |
5 | 5 | $41.2M | Series A Feb 2022 |
| Saint Medical saint-medical.com |
5 | 5 | — | Series A Oct 2022 |
| Hongyun Biotech redcloudbio.com |
5 | 5 | — | Series B May 2023 |
| Legend Biotechnology legendbiotech.com |
4 | 4 | $601.8M | Series D Mar 2020 |
| Crystal Nucleus Biomedical Technology crystalnucleusbiomedicaltechnology.vdtrxn |
4 | 4 | — | Seed Aug 2022 |
| Novlead novlead.com |
3 | 3 | $56.4M | Series B Nov 2021 |
| Iongen Therepeutics iongentherapeutics.com |
3 | 3 | $40.8M | Seed Jan 2025 |
| Yinuo Pharmaceutical yinuopharmaceutical.vdtrxn |
3 | 3 | $17.8M | Seed Feb 2023 |
| Yigao njeco.cn |
3 | 3 | — | Unattributed Apr 2022 |
| Tingsn tingsn.com |
3 | 3 | — | Series A Dec 2021 |
| Tuodao Medical tuodaomedical.com |
3 | 3 | — | Series A Apr 2022 |
| Ruichu Pharmaceutical ruichupharmaceutical.vdtrxn |
3 | 3 | — | Seed May 2024 |
| Heluo Xintu Biotechnology heluoxintubiotechnology.vdtrxn |
3 | 3 | — | Angel Feb 2023 |
| Nanjing Nuoyuan Medical nuoyuanmedical.cn |
2 | 2 | $31.6M | Series B Jan 2022 |
| Difei dinfectome.com |
2 | 2 | $30.8M | Series A Sep 2021 |
| Tuge Medical Tugemedical tugemedical.com |
2 | 2 | $14.3M | Series A Jul 2020 |
| Nanjing Xinrui Regenerative Medicine Technology xremed.com |
2 | 2 | — | Seed Feb 2022 |
| Qingpu Biotechnology delovabio.com |
2 | 2 | — | Seed Sep 2020 |
| Kaidi Medical kaidimedical.vdtrxn |
2 | 2 | — | Series A Mar 2022 |
| Xianwei Vision Technology xianweivisiontechnology.vdtrxn |
2 | 2 | — | Seed Jan 2023 |
| Frontier Biotechnologies frontierbiotech.com |
1 | 1 | $43.2M | Series C Dec 2016 |
| Nanjing Perlove Medical Equipment perlove.com.cn |
1 | 1 | — | PE Aug 2020 |
| Tenoke tenoke.com |
1 | 1 | — | Seed Jun 2016 |
| Newport Nanjing Biological Technology nnbnutritionchina.com |
1 | 1 | — | Series A Nov 2021 |
| Biotogether biotogether.com |
1 | 1 | — | Series A Dec 2010 |
| Nanjing Minowei Pharmaceutical Technology minovapharma.com |
1 | 1 | — | Series A Jan 2024 |
| mHealth365 mhealth365.cn |
1 | 1 | — | Series A Feb 2015 |
| Chengshi Biotechnology therarna.cn |
1 | 1 | — | Seed Mar 2023 |
| Fuhan Medical fuhanyiliao.com |
1 | 1 | — | Series A Jan 2024 |
| Date | Investor | Company | Stage | Round size |
|---|---|---|---|---|
| Jan 2025 | Qiming Venture Partners | Iongen Therepeutics | Seed | $13.6M |
| Jan 2025 | THG Ventures | Iongen Therepeutics | Seed | $13.6M |
| Jan 2025 | Insight Capital | Iongen Therepeutics | Seed | $13.6M |
| May 2024 | Delian Capital | Ruichu Pharmaceutical | Seed | — |
| May 2024 | Dingxin Capital | Ruichu Pharmaceutical | Seed | — |
| May 2024 | Longpan Investment | Ruichu Pharmaceutical | Seed | — |
| Apr 2024 | ShenZhen GTJA Investment GroupLED | Impact Therapeutics | Series D | $55.2M |
| Apr 2024 | Lilly Asia Ventures | Impact Therapeutics | Series D | $55.2M |
| Apr 2024 | C&D Emerging Industry Equity Investment | Impact Therapeutics | Series D | $55.2M |
| Apr 2024 | Xicheng JinruiLED | Impact Therapeutics | Series D | $55.2M |
| Apr 2024 | Yangzhou Guojin Investment Group | Impact Therapeutics | Series D | $55.2M |
| Jan 2024 | Jinmao InvestmentLED | Fuhan Medical | Series A | — |
| Jan 2024 | Wenzhou Investment | Nanjing Minowei Pharmaceutical Technology | Series A | — |
| Sep 2023 | Shanghai Guoxin Investment DevelopmentLED | Triastek | Series B | $20.4M |
| Sep 2023 | Goldmine | Triastek | Series B | $20.4M |
| May 2023 | Renjin Investment | Hongyun Biotech | Series B | — |
| May 2023 | Taizhou Angel Fund | Hongyun Biotech | Series B | — |
| May 2023 | Taizhou Huayin Financial Investment | Hongyun Biotech | Series B | — |
| May 2023 | Sherpa Invest | Hongyun Biotech | Series B | — |
| May 2023 | Lotus Lake Capital Management | Hongyun Biotech | Series B | — |
Life Sciences investors in other cities
Other markets in Nanjing